Mesenchymal Stem Cells for the Treatment of Hematological Malignancies
Allogeneic MSC have a fully therapeutic potential in HSCT and possibly in bone marrow failure. However, there are still some questions.
The therapeutic dose of MSC needed in clinics is still unknown. Repetitive infusion of MSC might be necessary to maintain the therapeutic effect and to get a sufficient level of chimerism. MSC are immunosuppressive, can induce tolerance, and decrease GVHD; actually these immunological effects might be deleterious on the graft versus tumor effect. The place of allogeneic MSC from unique donors needs to be evaluated. The place of genetically modified MSC in HSCT also needs to be evaluated.
KeywordsMesenchymal Stem Cell Hematopoietic Stem Cell Graft Versus Host Disease Bone Marrow Failure Severe Aplastic Anemia
Unable to display preview. Download preview PDF.
- Almeida-Porada G, Porada CD, Tran N, Zanjani ED (2000) Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood 95:3620–3627PubMedGoogle Scholar
- Benshidoum M et al. Transplantation of human bone marrow stromal cells (MSC) into immunodeficient mice. The improvement of human hematopoiesis maintenance and the extent of tissue engraftment depend on the studied MSC subsets. SubmittedGoogle Scholar
- Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman R (2001) Mesenchymal stem cells are capable of homing to the bone marrow of nonhuman primates following systemic infusion. Exp Hematol 29:244–255PubMedCrossRefGoogle Scholar
- Fouillard L, Benshidoum M, Bories D, Bonte H, Lopez M, Moseley AM, Smith A, Lesage S, Beaujean F, Thierry D, Gourmelon P, Najman A, Gorin NC (2003) Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe aplastic anemia improves stroma. Leukemia 17:474–476PubMedCrossRefGoogle Scholar
- Ishida T, Inaba M, Hisha H, Sugiura K, Adachi Y, Nagata N, Ogawa R, Good RA, Ikehara S (1994) Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune disease in MRL/ MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J Immunol 152:3119PubMedGoogle Scholar
- Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM (2000) Rapid hematopoietic recovery after coinfusion of autologous blood stem cells and culture expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high dose chemotherapy. J Clin Oncol 18:307–316PubMedGoogle Scholar
- Noort WA, Kruisselbrink AB, in’t Anker PS, Kruger M, van Bezooijen RL, de Paus RA, Heemskerk MH, Lowik CW, Falkenburg JH, Willemze R, Fibbe WE (2002) Mesenchymal stem cells promote engraftment of human umbilical cord blood derived CD34+ cells in NOD-SCID mice. Exp Hematol 30:870–878PubMedCrossRefGoogle Scholar